Research Center: Henry Ford Medical Center
Location: 39450 W 12 Mile Rd, Novi, Michigan 48377
Lead Researcher: Christopher Drake, PhD
IRB: This study has been reviewed and approved by the Henry Ford Health IRB and Advarral IRB

Did you know that many new mothers face challenges with postpartum depression (PPD), and traditional treatments don’t always help? That’s why researchers are exploring innovative solutions—like RE104, an investigational psychedelic medication similar to psilocybin. This study aims to see if a single dose of RE104 could help ease PPD symptoms.

Join Henry Ford Medical Center researchers in this potentially groundbreaking study that could change the future of PPD treatment! Discover if you qualify. Join today!

• Participants may receive a new potential treatment for postpartum depression at no cost.
• Participants may earn up to $918 for their involvement, receiving $150 for each attended study visit, with payments made at the end of each visit. If they do not complete the study, they will still be compensated for the visits they completed.
• Participants may experience improvements in symptoms related to PPD.
• Participants will be contributing valuable information that may benefit those with postpartum depression in the future.
• Participants will be helping to advance medical research.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Must be experiencing postpartum depression
• Must have started feeling symptoms during the second or third trimester or within the first month following birth
• Must not be more than 12 months postpartum
• Must not be breastfeeding or must be willing to stop breastfeeding if screened for the study
• Must not have ever been diagnosed with postpartum psychosis
• Must not have been diagnosed with depression prior to pregnancy or must specify the last depressive episode prior to giving birth
• Must not have been diagnosed with treatment-resistant depression in the last 12 months
• Must not have failed treatment with two different antidepressant medications, each taken for more than 4 weeks
• Must not have attempted suicide within the last year or have current suicidal ideation
• Must not have a medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder, borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
• Must not have a history of seizures other than childhood febrile seizures
• Must not have used any psychedelics in the past 12 months
• Must not have a known sensitivity or intolerance to hallucinogenic or psychedelic substances
• Must be willing and able to nominate a trusted caregiver for their infant for the duration of the dosing day and for 24 hours post-dose.
• Must not have any serious health issues that could affect the study, like neurological disorders, diabetes, lung-related high blood pressure, untreated thyroid problems, or severe liver or kidney disease
• Must not have a known sensitivity to benzodiazepines or anti-nausea medication
• Must be willing to come to the research site for 8-10 in-person visits 

Henry Ford Medical Center

The Henry Ford Sleep Research Center, founded in 1978, is one of the first sleep disorders centers in the United States and is consistently one of the top sleep research facilities in the nation. It is home of the Center for Behavioral Circadian Medicine and the Perinatal Sleep Health Institute and now has locations across Southeast Michigan. Our mission is to continuously improve sleep-wake health through the production, incorporation and dissemination of sleep research. We strive to foster multidisciplinary collaboration across HFH Women’s Health Clinics, behavioral health, and sleep medicine to support research and quality enhancement initiatives to improve care for pregnant and postpartum patients.